Skip to main content
Premium Trial:

Request an Annual Quote

ProterixBio Licenses Coronavirus Serology Test From Mass General

NEW YORK — ProterixBio said on Wednesday that it has licensed a SARS-CoV-2 serology test from Massachusetts General Hospital.

According to ProterixBio, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein. The test can be run using dried blood samples from finger pricks and includes a means of calibration so measurements can be tracked over time.

Developed by the Ragon Institute of Mass General, the Massachusetts Institute of Technology, and Harvard University, the test has been clinically evaluated in over 10,000 individuals and is being used in ongoing public health surveillance projects, the Billerica, Massachusetts-based company added.

Specific terms of the licensing deal were not disclosed.

ProterixBio said it intends to submit the test to the US Food and Drug Administration for Emergency Use Authorization, and that it expects to begin offering it as a clinical testing service in the third quarter of the year.